ACM
KYTX icon

AIGH Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

AIGH Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3M Buy
2,000,000
+500,000
+33% +$4.17M 2.35% 12
2025
Q4 		$14.1M Buy
+1,500,000
New +$11.1M 3.41% 11

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIGH Capital Management's KYTX Position: Q1 2026 in Review

AIGH Capital Management increased its Kyverna Therapeutics (KYTX) stake by 33% in Q1 2026, buying an estimated $4.17M and bringing the position to 2,000,000 shares worth $17.3M. The position accounts for 2.35% of the portfolio, ranked #12.

AIGH Capital Management first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • AIGH Capital Management held 2,000,000 shares of Kyverna Therapeutics worth $17.3M as of Q1 2026.
  • AIGH Capital Management bought 500,000 Kyverna Therapeutics shares in Q1 2026, an estimated $4.17M.
  • Kyverna Therapeutics made up 2.35% of AIGH Capital Management's portfolio in Q1 2026, its #12 holding.
  • AIGH Capital Management first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.